ViroPharma forges ahead with C Diff preventative
This article was originally published in Scrip
Executive Summary
ViroPharma has initiated a Phase II dose-ranging clinical study in North America of VP 20621, its drug to prevent recurrences of Clostridium difficile infection in adults previously treated with antibiotics.